var data={"title":"Rituximab and hyaluronidase (subcutaneous): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rituximab and hyaluronidase (subcutaneous): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/812397?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rituximab-and-hyaluronidase-subcutaneous-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rituximab and hyaluronidase (subcutaneous): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50313245\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mucocutaneous reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab-containing products, including rituximab/hyaluronidase.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatitis B virus reactivation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatitis B virus (HBV) reactivation can occur in patients treated with rituximab-containing products, including rituximab/hyaluronidase, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with rituximab/hyaluronidase. Discontinue rituximab/hyaluronidase and concomitant medications in the event of HBV reactivation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Progressive multifocal leukoencephalopathy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Progressive multifocal leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab-containing products, including rituximab/hyaluronidase.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50337646\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rituxan Hycela</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50313248\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD20;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336820\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> All patients must receive at least one full dose of intravenous rituximab (without experiencing severe adverse reactions) prior to initiating treatment with subcutaneous rituximab/hyaluronidase; patients who do not tolerate a full IV dose should continue to receive IV rituximab in subsequent cycles. May switch to SubQ rituximab/hyaluronidase when a full IV dose is successfully administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premedicate with acetaminophen and an antihistamine prior to each dose (consider glucocorticoid premedication if necessary). Antihyperuricemic therapy and aggressive hydration are recommended for patients at risk for tumor lysis syndrome (high tumor burden or lymphocytes &gt;25,000/mm<sup>3</sup>). In patients with chronic lymphocytic leukemia (CLL), <i>Pneumocystis jirovecii</i> pneumonia (PCP) and antiherpetic viral prophylaxis is recommended during treatment (and for up to 12 months following treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic lymphocytic leukemia:</b> SubQ: Rituximab 1,600 mg/hyaluronidase 26,800 units (fixed dose) on day 1 of a 28-day cycle in cycles 2 through 6 (in combination with fludarabine and cyclophosphamide) (Assouline 2016) (IV rituximab should be administered in cycle 1).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diffuse large B-cell lymphoma:</b> SubQ: Rituximab 1,400 mg/hyaluronidase 23,400 units (fixed dose) on day 1 of cycles 2 through 8 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (IV rituximab should be administered in cycle 1).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Follicular lymphoma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Previously untreated:</i> SubQ: Induction: Rituximab 1,400 mg/hyaluronidase 23,400 units (fixed dose) on day 1 of a 21-day cycle in cycles 2 through 8 (in combination with chemotherapy) (Davies 2017); IV rituximab should be administered in cycle 1. In patients with complete or partial response following combination chemotherapy, initiate maintenance treatment (see below).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> SubQ: In patients with complete or partial response, initiate rituximab 1,400 mg/hyaluronidase 23,400 units (fixed dose) once every 8 weeks for 12 doses (Davies 2017). Maintenance treatment should be initiated 8 weeks following completion of initial combination chemotherapy treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-progressing disease following 6 to 8 cycles of first-line CVP chemotherapy:</i> SubQ: Rituximab 1,400 mg/hyaluronidase 23,400 units (fixed dose) once weekly for 3 weeks (IV rituximab should be administered in week 1 for a total of 4 weeks of therapy) at 6-month intervals to a maximum of 16 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Relapsed or refractory:</i> SubQ: Rituximab 1,400 mg/hyaluronidase 23,400 units (fixed dose) once weekly for 3 or 7 weeks (IV rituximab should be administered in week 1) for a total of 4 or 8 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Relapsed or refractory (retreatment):</i> SubQ: Rituximab 1,400 mg/hyaluronidase 23,400 units (fixed dose) once weekly for 3 weeks (IV rituximab should be administered in week 1) for a total of 4 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Relapsed or refractory (maintenance treatment after response to induction treatment) [Canadian labeling]:</i> SubQ: 1,400 mg (fixed dose) once every 3 months until disease progression or maximum duration of 2 years (Rituxan SC Canadian product labeling 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336821\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336822\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336823\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336824\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage adjustments for rituximab/hyaluronidase are not recommended; however, adjustments for concomitant chemotherapy may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50351707\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rituxan Hycela: Rituximab 1400 mg and hyaluronidase human 23,400 units per 11.7 mL (11.7 mL); Rituximab 1600 mg and hyaluronidase human 26,800 units per 13.4 mL (13.4 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50351706\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336831\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage Forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Subcutaneous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rituxan SC: 1,400 mg/11.7 mL (15 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50324445\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761064s000lbl.pdf#page=29&amp;token=sgue1VRxbi89Ggz7GyoGbyn+rAF1I7yFgKokqEf26sqoJZ+dcdrxfA4KQoDOGGpd477irotFR2JVkKU9iIAH/oOHAUVZo/9sISl4U2naVP5GF3pCQN7/xyhcMs8D2CeG&amp;TOPIC_ID=113786\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761064s000lbl.pdf#page=29</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336826\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: For SubQ administration only. Inject subcutaneously into the abdomen over approximately 5 minutes (rituximab 1,400 mg/hyaluronidase 23,400 units) to 7 minutes (rituximab 1,600 mg/hyaluronidase 26,800 units). Do not inject into areas where the skin is red, bruised, tender or hard, or where there are moles or scars. If administration is interrupted, continue administration at the same or at a different site (restricted to the abdomen). Monitor patients for 15 minutes following administration. To avoid clogging the needle, attach the injection needle to the syringe immediately prior to administration; rituximab/hyaluronidase is compatible with polypropylene and polycarbonate syringes and stainless steel transfer and injection needles. Do not administer other subcutaneous medications at the same sites as rituximab/hyaluronidase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50313250\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia:</b> Treatment of adult patients with previously untreated and previously treated chronic lymphocytic leukemia (CLL) (in combination with fludarabine and cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diffuse large B-cell lymphoma:</b> Treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Follicular lymphoma:</b> Treatment of adult patients with:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relapsed or refractory follicular lymphoma (FL) as a single agent;</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Previously untreated FL (in combination with first-line chemotherapy) and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy (as single-agent maintenance therapy);</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-progressing (including stable disease) FL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Initiate treatment with rituximab/hyaluronidase only after patients have received at least 1 full dose of a rituximab product by intravenous infusion; rituximab/hyaluronidase is not indicated for the treatment of non-malignant conditions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336699\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Rituxan Hycela may be confused with Rituxan, Remicade</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">RiTUXimab/hyaluronidase may be confused with brentuximab, bevacizumab, inFLIXimab, obinutuzumab, ofatumumab, ramucirumab, rituximab, ruxolitinib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Rituximab/hyaluronidase is for subcutaneous (SubQ) administration only. Do not substitute rituximab (IV) for rituximab/hyaluronidase (SubQ). Use caution during product selection, preparation, and administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50353040\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see individual agents. All incidences are from combination therapy regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (11% to 20%), paresthesia (9% to 16%), headache (6% to 13%), peripheral neuropathy (12%; grades 3/4: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (14% to 24%), allergic skin reaction (16%; pain, swelling, induration, hemorrhage, erythema, pruritus, and rash, as well as injection site reactions), erythema (9% to 15%), skin rash (10% to 12%; including severe mucocutaneous reactions)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (22% to 38%), constipation (8% to 25%), vomiting (11% to 21%), diarrhea (14% to 18%), abdominal pain (7% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (31% to 65%; grades 3/4: 25% to 56%), anemia (15% to 23%; grades 3/4: 5%), leukopenia (6% to 19%; grades 3/4: 3% to 4%), febrile neutropenia (8% to 14%; grades 3/4: 7% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (anti-hyaluronidase antibodies: 11% to 13%; anti-rituximab antibodies: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Serious infection (46% to 56%; including reactivation of viral infections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (13% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (8% to 17%), arthralgia (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (11% to 23%), upper respiratory tract infection (13% to 15%), dyspnea (4% to 11%), pneumonia (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (13% to 32%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (5% to 8%), chest pain (6%), hypertension (6%), hypotension (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (8% to 13%), insomnia (1% to 9%), dizziness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (8% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (8%), dyspepsia (5% to 8%), mucosal inflammation (5% to 8%), stomatitis (6%), upper abdominal pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (2% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (5%; grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (8% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (7% to 10%), ostealgia (6% to 10%), back pain (9%), muscle spasm (8%), myalgia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (10%), oropharyngeal pain (6% to 9%), bronchitis (7% to 8%), sinusitis (7%), flu-like symptoms (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: JC virus infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (&le;7% monotherapy in maintenance setting; higher with combination therapy and initial infusions)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bone marrow depression, bronchiolitis obliterans, hypogammaglobulinemia (prolonged), interstitial pulmonary disease, intestinal obstruction, intestinal perforation, Kaposi sarcoma (disease progression), lupus-like syndrome, optic neuritis, pancytopenia (prolonged), pleurisy, polyarthritis, progressive multifocal leukoencephalopathy, serum sickness, uveitis, vasculitis (systemic; with rash), viral infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50313251\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Known type 1 hypersensitivity or anaphylactic reaction to murine proteins, Chinese Hamster Ovary (CHO) cell proteins, or any component of the formulation; patients who have or have had progressive multifocal leukoencephalopathy (PML); patients with severe, active infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336703\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concerns related to adverse effects:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel obstruction/perforation: Abdominal pain, bowel obstruction, and perforation have been reported (rarely fatal) in patients receiving rituximab-containing products, with an average onset of symptoms of ~6 days (range: 1 to 77 days); evaluate abdominal pain or repeated vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Cardiac events (eg, ventricular fibrillation, myocardial infarction, and cardiogenic shock) may occur with rituximab-containing products. Discontinue rituximab/hyaluronidase for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after administration in patients who develop clinically significant arrhythmias or who have a history of arrhythmia or angina.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytopenias: Rituximab is associated with lymphopenia, leukopenia, neutropenia, thrombocytopenia, and anemia; the duration of cytopenias may be prolonged and may extend months beyond treatment. Monitor blood counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B virus reactivation:<b> [US Boxed Warning]: Hepatitis B virus (HBV) reactivation may occur with rituximab-containing products, including rituximab/hyaluronidase, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with rituximab/hyaluronidase. Discontinue rituximab/hyaluronidase and concomitant medications in the event of HBV reactivation.</b> Screening should include hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc); monitor patients for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months after treatment. If viral hepatitis develops, initiate appropriate antiviral therapy. Reactivation has occurred in patients who are HBsAg positive as well as in those who are HBsAg negative but are anti-HBc positive; HBV reactivation has also been observed in patients who had previously resolved HBV infection. HBV reactivation has been reported up to 24 months after rituximab discontinuation. Use cautiously in patients who show evidence of prior HBV infection (eg, HBsAg positive [regardless of antibody status] or HBsAG negative but anti-HBc positive); consult with appropriate clinicians regarding monitoring and consideration of antiviral therapy before and/or during rituximab treatment. The safety of resuming rituximab-containing treatment following HBV reactivation is not known; discuss reinitiation of therapy in patients with resolved HBV reactivation with physicians experienced in HBV management.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- American Society of Clinical Oncology (ASCO) provisional clinical opinion update on hepatitis B virus screening recommendations (Hwang 2015): Patients receiving anti-CD20 antibodies are at high risk for hepatitis B virus (HBV) reactivation. Screen for HBV infection with HBsAG and anti-HBc tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). In addition, patients who have risk factors for HBV infection (eg, birthplace in a country with &ge;2% HBV prevalence, household or sexual contact with HBV infected patients, high-risk behaviors [eg, intravenous drug use], and HIV infection) should also be screened prior to beginning therapy. Initiate prophylactic antiviral therapy (utilizing antivirals with low rates of viral resistance) for HBsAg positive/anti-HBc positive patients (without delaying cancer therapy) and continue the antivirals during and for ~6 to 12 months after completing treatment. HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment; antiviral therapy may be initiated prophylactically or begun promptly at the first sign of HBV reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Rituximab-containing products are associated with hypersensitivity reactions (may be related to cytokine release and/or other chemical mediators). Due to the higher risk of hypersensitivity and other acute reactions, patients must receive at least one full dose of intravenous rituximab prior to receiving subcutaneous rituximab/hyaluronidase. Infusion-related reactions (with the use of intravenous rituximab formulations) usually occur within 30 to 120 minutes and may include hypotension, angioedema, bronchospasm, hypoxia, urticaria, and in more severe cases pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, and/or anaphylactoid events. Anaphylactic and other hypersensitivity reactions may occur (typically occur within minutes of infusion initiation); severe cytokine release syndrome may occur within 1 to 2 hours of starting infusion. Patients with a history of pulmonary insufficiency or with pulmonary tumor infiltration may have a poorer outcome. Closely monitor patients with a history of prior cardiopulmonary reactions or with preexisting cardiac or pulmonary conditions and patients with high numbers of circulating malignant cells (&gt;25,000/mm<sup>3</sup>). Prior to administration, premedicate patients with acetaminophen and an antihistamine (and consider glucocorticoids). Observe patients for at least 15 minutes following subcutaneous administration; increase observation time in patients at higher risk of hypersensitivity reactions. Interrupt rituximab/hyaluronidase administration immediately for signs of a severe reaction; initiate aggressive symptomatic treatment. Medications for the treatment of hypersensitivity reactions (eg, bronchodilators, epinephrine, antihistamines, corticosteroids) should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Serious and potentially fatal bacterial, fungal, and either new or reactivated viral infections may occur during treatment and after completing therapy with rituximab-containing products. Infections have been observed in patients with prolonged hypogammaglobulinemia, defined as hypogammaglobulinemia &gt;11 months after rituximab exposure. Associated new or reactivated viral infections have included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue rituximab/hyaluronidase in patients who develop serious infections and initiate appropriate anti-infective treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucocutaneous and cutaneous reactions: <b>[US Boxed Warning]: Severe, including fatal, mucocutaneous reactions may occur in patients receiving rituximab-containing products, including rituximab/hyaluronidase.</b> Paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis have been reported. Discontinue in patients experiencing severe mucocutaneous skin reactions; the safety of reexposure following mucocutaneous reactions has not been evaluated. Subcutaneous rituximab has been associated with localized cutaneous (and injection site) reactions (eg, pain, erythema, swelling, induration, rash, pruritus, hemorrhage); may occur &gt;24 hours after administration. Reactions have been mostly mild to moderate and have resolved without intervention. Local reactions were most common during the first rituximab/hyaluronidase cycle (incidence decreases with subsequent injections).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: <b>[US Boxed Warning]: Progressive multifocal leukoencephalopathy (PML) (including fatalities) may occur in patients receiving rituximab-containing products, including rituximab/hyaluronidase.</b> Promptly evaluate any patient presenting with neurological changes; consider neurology consultation, brain MRI and lumbar puncture for suspected PML. Discontinue rituximab/hyaluronidase in patients who develop PML; consider reduction/discontinuation of concurrent chemotherapy or immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Rituximab-containing products may cause severe or fatal renal toxicity. Patients who received combination therapy with cisplatin and rituximab for NHL experienced renal toxicity (associated with tumor lysis syndrome) during clinical trials; this combination is not an approved treatment regimen. Renal toxicity also occurred due to tumor lysis syndrome. Monitor for signs of renal failure; discontinue rituximab-containing products with increasing serum creatinine or oliguria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome may occur within 12 to 24 hours after administration of a rituximab-containing product. Hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia may occur. Administer prophylaxis (antihyperuricemic therapy, hydration) in patients at high risk (high numbers of circulating malignant cells &ge;25,000/mm<sup>3</sup> or high tumor burden). Correct electrolyte abnormalities; monitor renal function and hydration status, and administer supportive care as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live vaccines should not be given concurrently with rituximab; there is no data available concerning secondary transmission of live vaccines with or following rituximab-containing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50354213\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50354210\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=113786&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: RiTUXimab may enhance the adverse/toxic effect of Abatacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<b> Exceptions: </b>EPINEPHrine (Nasal); EPINEPHrine (Oral Inhalation); Isometheptene; Pseudoephedrine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: RiTUXimab may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<b> Exceptions: </b>Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOPamine: Hyaluronidase may enhance the adverse/toxic effect of DOPamine.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine.  Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. <b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic).  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: RiTUXimab may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336701\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Rituximab crosses the placenta; B-cell lymphocytopenia lasting &lt;6 months may occur in exposed infants. Effective contraception should be used in women of reproductive potential during therapy and for 12 months following treatment. Refer to individual monographs for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336702\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rituximab or hyaluronidase are present in breast milk. However, human IgG is excreted in breast milk; therefore, rituximab may be present. According to the manufacturer, lactating women should not breastfeed during therapy or for at least 6 months after treatment is complete. Refer to individual monographs for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336828\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Electrolytes (in patients at risk for TLS), CBC with differential; renal function (in patients at risk for TLS), fluid/hydration status balance; blood pressure, vital signs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Screen all patients for HBV infection prior to therapy initiation (eg, HBsAG and anti-HBc measurements). In addition, carriers and patients with evidence of current infection or recovery from prior hepatitis B infection should be monitored closely for clinical and laboratory signs of HBV reactivation and/or infection during therapy and for up to 2 years following completion of treatment. Hepatitis B virus (HBV) screening recommendations (ASCO provisional clinical opinion update [Hwang 2015]): Screen for HBV infection with hepatitis B surface antigen (HBsAG) and hepatitis B core antibody (anti-HBc) tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for hypersensitivity reactions (observe for 15 minutes following administration); signs of active hepatitis B infection (during and for up to 12 months after therapy completion); cardiac monitoring during and after infusion (in patients with preexisting cardiac disease or if arrhythmias develop during or after subsequent infusions); monitor for signs/symptoms of bowel obstruction/perforation (abdominal pain, vomiting); signs or symptoms of progressive multifocal leukoencephalopathy (focal neurologic deficits, which may present as hemiparesis, visual field deficits, cognitive impairment, aphasia, ataxia, and/or cranial nerve deficits); signs/symptoms of TLS and/or mucocutaneous or cutaneous skin reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336707\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of pre-B and mature B-lymphocytes. CD20 regulates cell cycle initiation; and, possibly, functions as a calcium channel. Rituximab binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase increases the absorption rate of rituximab-containing products by increasing permeability of subcutaneous tissue through temporary depolymerization of hyaluronan; at the recommended doses, hyaluronidase acts locally and the effects are reversible. Permeability of the subcutaneous tissue is restored within 24 to 48 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50336708\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CLL: B-cells begin to deplete following the first cycle of rituximab, with 28% of patients B-cell depleted prior to the dose in cycle 2; by cycle 6, 96% of patients were B-cell depleted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FL: Peripheral B-cell counts decrease to levels below normal following the first cycle of rituximab and are maintained during treatment with rituximab/hyaluronidase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CLL: Patients remained B-cell depleted until month 9, where signs of repletion were seen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FL: After discontinuing rituximab/hyaluronidase, B-cell repletion begins after 6 months (may be longer in some patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: SubQ: 8.52 L (CLL); 8.09 L (FL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability (compared to IV rituximab): SubQ: 63.4% (CLL); 64.6% (FL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (terminal): 32 days (CLL); 34.1 days (FL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50454590\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rituxan Hycela Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1400-23400 MG-UT/11.7ML (11.7 mL): $7,588.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600-26800 MG-UT/13.4ML (13.4 mL): $8,672.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3960626\"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26947201\"></a>Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomized controlled non-inferiority trial. <i>Lancet Haematol.</i> 2016;3(3):e128-e138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/26947201/pubmed\" target=\"_blank\" id=\"26947201\">26947201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6423951\"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28476440\"></a>Davies A, Merli F, Mihalijevic B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomized, open-label, phase 3 trial. <i>Lancet Haematol.</i> 2017;4(6:e272-e282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/28476440/pubmed\" target=\"_blank\" id=\"28476440\">28476440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25964247\"></a>Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. <i>J Clin Oncol</i>. 2015;33(19):2212-2220. doi: 10.1200/JCO.2015.61.3745.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/25964247/pubmed\" target=\"_blank\" id=\"25964247\">25964247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12534540\"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10985636\"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rituxan Hycela (rituximab and hyaluronidase human) [prescribing information]. South San Francisco, CA: Genentech Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rituxan SC (rituximab) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 113786 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50313245\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50337646\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50313248\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50336820\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50336821\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50336822\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50336823\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F50336824\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50351707\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50351706\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50336831\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50324445\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50336826\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50313250\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50336699\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50353040\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50313251\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50336703\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50354213\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50354210\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50336701\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50336702\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50336828\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50336707\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50336708\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50454590\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/113786|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rituximab-and-hyaluronidase-subcutaneous-patient-drug-information\" class=\"drug drug_patient\">Rituximab and hyaluronidase (subcutaneous): Patient drug information</a></li></ul></div></div>","javascript":null}